The object of this study was to determine the sensitivity and specificity of the Cozart RapiScan onsite saliva test for methadone and opiates versus laboratory-based enzyme immunoassay (ElM and gas chromatography-mass spectrometry (GC-MS) confirmation. Fifty saliva specimens were obtained from 28 volunteers among persons entering a substance abuse clinic. Specimens were tested onsite using the Cozart RapiScan Saliva test and Cozart RapiScan Reader. Specimens were retested by Cozart Microplate EIA assays on receipt at the laboratory and then frozen for later confirmation by GC-MS. For GC-MS, deuterated internal standards were added to specimen aliquots which were extracted using solid-phase columns at pH 6 and eluted with dichloromethane/isopropanol/ammonia (80:19:2). The dry residues were derivatized with PFOH and PFPA and dried, and the reconstituted extract was injected and quantitated by GC-MS. The Cozart RapiScan Methadone Saliva Assay was found to have a sensitivity and specificity of 100% • 12% versus GC-MS (2-ng/mL cutoff) and a sensitivity of 100% • 11% and a specificity of 95% -+ 2.4% versus the Microplate EIA for methadone (30-ng/mL cutoff). The Cozart RapiScan Saliva Opiate test had a sensitivity of 100% • 12% and a specificity of 92% _+ 3.2% versus GC-MS (2-ng/mL cutoff) and a sensitivity of 96% • 2.2% and specificity of 95% • 2.4% versus the Microplate EIA for opiates (30-ng/mL cutoff).
Introduction
Saliva or oral fluid has many advantages for collection and onsite testing for drugs of abuse (1) (2) (3) . Saliva collection is noninvasive and can be done by the donors themselves in most situations. It is difficult to adulterate or substitute oral fluid specimens as substances held in the mouth will dissipate, be swallowed or spit out during the 10-rain observation period before collection of the specimen (4) . Drug presence in saliva can frequently be correlated with drug concentrations of the free parent drug and lipophilic metabolites circulating in blood (5) .
In this study, methods for confirmation of oral fluid drug-positive results for drugs of abuse by gas chromatography-mass spectrometry (GC-MS) were developed and applied to oral fluid specimens from clients of a substance abuse clinic. The onsite results for the Cozart RapiScan Saliva Test system for methadone and for opiates were compared with the results on the fresh specimens for a laboratory-based microtiter plate enzyme immunoassay and with GC-MS results on the same specimens after freezing. The sensitivity and specificity of the onsite oral fluid tests were calculated for methadone and opiates.
Methods

Subjects
Persons entering the clinic at Ferry Cross (Substance Misuse Services, Norwich, U.K.) were asked to volunteer to give a saliva specimen in addition to the usual urine specimen required at the visit. The Ferry Cross Substance Misuse Services clinic issues prescriptions for methadone, and the methadone is dispensed at a pharmacy. The patients give a urine specimen before receiving the methadone. Fifty specimens were obtained from 28 people. An additional 30 saliva specimens were obtained from drug-free volunteers.
Cozart Rapiscan Saliva Drug Test
The Cozart RapiScan Saliva Drug Test is a lateral flow immunoassay employing colloidal gold-labeled antibodies to drugs of abuse. Drugs are immbolized to the membrane in rows. Saliva and buffer added to the cassette rehydrate the goldlabeled anti-drug antibodies contained within the cartridge. This mixture travels by capillary action across the array of immobilized drug sites. Presence of a given drug in the saliva results in a decrease in the corresponding drug line intensity at an immobilized drug position. The test results are read by the Cozart RapiScan instrument and displayed as positive and negative on the screen. The Cozart RapiScan test cartridge has a built-in reference line that is designed to show that sufficient sample has been added to the cartridge. If insufficient sample is added, the cartridge cannot be read by the instrument and the message "Reference Band Not Detected (RBND)" is displayed on the screen.
The Cozart RapiScan Saliva Drug Test was employed for onsite saliva drug testing as follows: 1 mL of oral fluid was collected from each subject on each occasion using the Cozart Saliva Collector. When placed in the mouth, the collection pad absorbed exactly I mL of saliva as indicated by a blue indicator in the handle. The saliva-soaked pad was then placed in the tube containing run buffer and separated from the plastic handle. The I mL of saliva on the cellulose pad was diluted with 2 mL of run buffer fluid to a final volume of 3 mL. Four drops (approximately 120 ]JL) of mixed saliva and buffer was removed and applied to the Cozart RapiScan cassette. A fresh disposable cassette, collection kit, and pipette were used for each test. After adding the saliva and buffer to the cassette, the cassette was inserted into the hand-held Cozart RapiScan instrument for incubation, which is 6 min for the dual opiates/methadone test (OPI/MTD test). After the incubation, the Cozart RapiScan reader indicated "Positive" or "Negative" for each of the drug classes.
The tubes of oral fluid-buffer mixture were capped, and the remainder of the sample was sent by post to Cozart where the diluted saliva was retested using the Cozart RapiScan and the Cozart microplate tests for Specific Morphine, Opiates, and Methadone. The remaining fluid was stored frozen for several months until all specimens were collected and then shipped to Tricho-Tech (Cardiff, Wales) for GC-MS analysis.
Cozart enzyme immunoassay (EIA) microplate assays
The Cozart microplate EIA assays were used to assay the mixed saliva and run buffer fluid which remained in the collection tubes. These are antibody-coated microtiter plates employing a drug-derivative that is labeled with horseradish peroxidase. Depending on the assay, either 25-, 10-, or 5-]JL sample, calibrator, or control was added to each well of the coated rnicrotiter plate followed by 100 ]~L of working enzyme conjugate. After a 30-min incubation, the plate was washed four times with 350 ]~L wash buffer, and then 100 IJL of substrate 
GC-MS procedure
Specimens were allowed to come to room temperature, and 100-300 IlL was removed for analysis. Deuterated internal standards (stock solutions 1 1Jg/mL) were added, and samples were extracted by solid-phase extraction on Oasis | MCX SPE columns (Oasis, Watford, U.K.) at pH 6. The columns were conditioned following the manufacturer's instructions. The mixed sample/internal standard aliquot was drawn through the column at a flow rate of less than I mL/min. The column was washed with 2 mL of deionized water. The column was dried under full vacuum for 5 min, and then elution was carried out with I mL of dichloromethane/isopropanol (90:10, v/v) with 2% ammonia (Fisher, Loughborough, U.K.). The eluted extracts were taken to dryness. The dry residues were derivatized with 50 l~L 2,2,3,3,3-pentafluoropropanol (PFOH) and 50 lJL of pentafluoropropionic anhydride (PFPA) at 70~ for 30 min. The dried and reconstituted extract was injected into the Hewlett-Packard model 5973 GC-MS, which was run in SIM mode. The chromatographic separation was carried out on a 15-m BPX5 (SGE, Milton Keynes, U.K.) capillary column with the following settings: injection port, 280~ splitless injection; initial oven temperature, 140~ held for 1 rain, then increased 20~ to 280~ then 40~ to 310~ and held for 3 rain. Detection was achieved by monitoring the following ions: 414 (577, 361) for morphine; 282 (445, 388) for codeine; 447 (284, 390) for dihydrocodeine; 414 (473, 361) for 6-monoacetylmorphine (6-MAM); 327 (369, 310) for heroin; 72 (165, 294) for methadone; and 277 (262, 248) for 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP). The first ion was used for quantitation. The following deuterated internal standards were monitored: morphine-d3417 (580); codeine-d6 288 (451); 6-MAM-d6 417 (479), heroin-d9 334 (378); and EDDP-d3 280 (279). A standard curve was constructed by analyzing standards at 0, 2, 8, 20, and 100 ng/mL for both morphine and methadone. GC-MS cutoffs for saliva were methadone 2 ng/mL and morphine 2 ng/mL. Standards and deuterated standards were obtained from Promochem (Hertfordshire, U.K.).
Precision
The Cozart RapiScan Saliva Test intra-assay precision was calculated by testing 20 replicates of a blank sample (no drug present) and 20 replicates of a sample at the cutoff concentration on the same day. The interassay precision was calculated by testing a blank sample (no drug present) and a sample at the cutoff concentration on 20 different days.
Accuracy
Eight saliva samples from different individuals were fortified with methadone and morphine at concentrations 50% above and 50% below the cutoff concentration. These were tested in the Cozart RapiScan Saliva Test system for methadone and opiates.
Cross.reactivity
Cross-reactivity for the Cozart RapiScan opiate/methadone (OPI/MTD) test was determined by dropping Cozart RapiScan run buffer spiked with drug derivatives (see Table I ) at a number of concentrations into the sample well and determining the response of the Cozart RapiScan test. Cross-reactivity was tested at 5, 10, 100, and 1000 ng/mL drug with the following exceptions, dihydrocodeine was at 1, 5, 100, and 1000 ng/mL; morphine-3-glucuronide was at 10, 15, 100, and 1000 ng/mL; and nalorphine was tested at 10,000 ng/mL only. Each concentration was tested in duplicate.
Sensitivity and specificity
Sensitivity was calculated as the TP/(TP + FN) and specificity as TN/(TN + FP) where TP is the number of true-positive results in persons administered the drug methadone or specimens positive by GC--MS, TN is the number of true-negative results in people not taking the drug or specimens negative by GC-MS, FN is the number of false-negative results in persons given the drug or specimens positive by GC-MS, and FP is the number of false-positive results in persons not taking the drug or specimens negative by GC-MS. The standard error of the sensitivity and specificity was calculated as SE = square root of pq/n where p is the sensitivity or specificity expressed as a decimal number, q = 1 -p, and n is the sample size. Table II shows the test results on saliva for methadone for the 50 specimens by the Cozart RapiScan, the Cozart microplate, and the GC-MS. As previously reported (2,6-8) methadone predominates in saliva with lesser amounts of EDDP found in some but not all specimens. Table III shows the Cozart RapiScan results for opiates, the Cozart Microplate results for specific morphine and for opiates and the GC-MS results for morphine, dihydrocodeine, codeine, 6-MAM, and heroin in the 50 saliva specimens from the substance misuse clinic. As previously reported (2,9), after heroin use, 6-MAM was present in saliva in concentrations equal to or higher than morphine except in those donors who also had high concentrations of dihydrocodeine or codeine in their saliva. This allowed interpretation of the source of the opiate positive.
Results
The Cozart RapiScan uses cutoff concentrations of 10 ng/mL morphine and 10 ng/mL methdone. With the dilution factor of three in the Cozart RapiScan procedure, these cutoffs concentrations are equivalent to saliva concentrations of 30 ng/mL morphine or 6-MAM and 30 ng/mL methadone. When eight saliva samples from different individuals fortified with methadone and morphine at concentrations at 50% above and 50% below the cutoff concentration were tested in the Cozart RapiScan Saliva Test system for methdone and opiates, all samples at 50% above the concentration were positive for methadone and opiates and all samples at 50% below the cutoff concentration were negative for methadone and opiates.
The crossreactivity of the Cozart RapiScan tests for opiates are shown in Table I . When these derivatives were tested at high concentrations (10,000 ng/mL) using the OPI/MTD test, the methadone response was negative. In general, the Cozart RapiScan targets the parent drug, which is the predominate analyte in saliva (9,10) rather than the urine metabolites commonly screened for in urine testing.
The Cozart RapiScan Saliva Test had intra-assay and interassay precisions of 0.5% CV and 2.3% CV, respectively, for methadone in oral fluid at the cutoff of 10 ng/mL methadone and of 0.6% CV and 2.6% CV, respectively, for opiates at the cutoff of 10 ng/mL morphine. The intra-assay and interassay precision of the blanks (no drug present) were 2.9% CV and 16.7% CV for the methadone test and 4.7% CV and 16.2% CV for opiates, respectively. Figure 1 shows the true negatives, false positives, false negatives, and true positives for the Cozart RapiScan Saliva test versus GC-MS for methadone and opiates. Figure 2 shows the true negatives, false positives, false negatives, and true positives for the Cozart Microplate EIAs versus GC-MS. From this study the Cozart RapiScan Methadone Saliva Assay was found to have a sensitivity and specificity of 100% • 12% versus GC-MS (2-ng/mL cutoff) and a sensitivity of 100% • 11% and a specificity of 95% + 2.4% versus the Microplate EIA for methadone (30-ng/mL cutoff). The Cozart RapiScan Saliva Opiate test had a sensitivity of 100% • 12% and a specificity of 92% • 3.2% versus GC-MS (2-ng/mL cutoff) and a sensitivity of 96% • 2.2% and specificity of 95% • 2.4% versus the Microplate EIA for opiates (30-ng/mL cutoff) (Table IV) .
Conclusions
Onsite oral fluid testing with the Cozart RapiScan Saliva Test for methadone and for opiates provides a sensitive and specific method for screening for evidence of methadone in saliva as proof of compliance with methadone dosing and for opiates as an indicator of abstinence. The oral fluid collected and preserved with buffer in the Cozart RapiScan system can be retested by EIA or confirmed with GC-MS for the drugs indicated by the onsite screen.
